Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamfetamine transdermal - Noven Pharmaceuticals

Next Previous
Drug Profile

Dexamfetamine transdermal - Noven Pharmaceuticals

Alternative Names: ATS; d-Amphetamine Transdermal System; d-ATS; Dextroamphetamine transdermal system - Noven; SPD-487; XELSTRYM

Latest Information Update: 19 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Noven Pharmaceuticals
  • Class Amphetamines; Behavioural disorder therapies; Sleep disorder therapies
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 05 Jun 2023 Launched for Attention-deficit hyperactivity disorder (In adults, In adolescents, In children) in USA (Transdermal)
  • 23 Mar 2022 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (Transdermal)
  • 27 Apr 2021 Safety and efficacy data from a phase IIa trial in Attention-deficit hyperactivity disorder released by Noven Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top